Johnson & Johnson announced on August 24 that the FDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older previously or currently treated with corticosteroids. It is the first FDA-approved treatment for wAIHA. The approval adds the first treatment option for this rare blood disorder and marks the expansion […]
- info-gsls@greenstafflifesciences.com
- Mon - Fri: 9.00 - 18.00 (JST)
- Accessibility